Snipd home pageGet the app
public
The Readout Loud chevron_right

269: Biotech layoffs, eye drug drama, & gene therapy milestones

Aug 3, 2023
37:27
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 4min
chevron_right
2
Celsius: A Case Study of a Biotech Startup's Future
04:17 • 5min
chevron_right
3
The End of EQRx
09:35 • 5min
chevron_right
4
The Difficult Decisions to Make Based on the Macro Environment
14:17 • 5min
chevron_right
5
Sereptus: A Gene Therapy for Duchenne
19:16 • 2min
chevron_right
6
The Challenges of Gene Therapy for Hemophilia A
20:50 • 2min
chevron_right
7
The Decline of Demand for COVID-19 Vaccines
23:20 • 2min
chevron_right
8
The Future of COVID-19 Vaccines
24:50 • 1min
chevron_right
9
The Conflict of Interests With a Pelvic Pharmaceuticals
26:17 • 5min
chevron_right
10
The Conflict of Interests in Pharmaceutical Drug Development
30:58 • 3min
chevron_right
11
The Role of Appellist in the Development of a Drug for Eye Infections
33:34 • 4min
chevron_right
First, we discuss how some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.
HomeTop podcastsPopular guestsTop books